SCHEMBL2013480

SCHEMBL2013480

Cc1cc(O)c2cnn(-c3ccc(OCc4ccccc4)c(F)c3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.40
S1PR5 Q9H228 1/20 0.38
ERN1 O75460 1/20 0.38
MAPK14 Q16539 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TSHR P16473 2/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.37
ALDH1A2 O94788 1/20 0.36
ALDH1A3 P47895 1/20 0.36
NR3C1 P04150 4/20 0.35
MAOB P27338 2/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
GSK3B P49841 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
MAPT P10636 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2004763 0.90 S1PR5 (0.39) MRGPRX4S1PR5ERN1MAPK14ALDH1A1
SCHEMBL2009960 0.89 ERN1 (0.41) S1PR5ERN1MAPK14ALDH1A1KDM4E
SCHEMBL2006708 0.88 MRGPRX4 (0.40) MRGPRX4S1PR5ERN1MAPK14TSHR
SCHEMBL2008520 0.88 MAPK14 (0.42) MRGPRX4S1PR5MAPK14ALDH1A1TSHR
SCHEMBL2003916 0.86 S1PR5 (0.40) MRGPRX4S1PR5ERN1MAPK14ALDH1A1
SCHEMBL12572463 0.85 S1PR5 (0.36) MRGPRX4S1PR5ERN1MAPK14ALDH1A1
SCHEMBL2006324 0.85 MAPT (0.37) S1PR5MAPK14ALDH1A1TSHRKDM4E
SCHEMBL14085379 0.83 MAPK14 (0.41) MRGPRX4S1PR5ERN1MAPK14ALDH1A1
SCHEMBL14085312 0.82 CYP11B1 (0.42) MRGPRX4S1PR5MAPK14NR3C1MAPT
SCHEMBL2005842 0.82 ERN1 (0.41) MRGPRX4S1PR5ERN1MAPK14TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB MRGPRX4 292/4885S1PR5 2298/4885ERN1 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.